Breast cancer patients with ER mutations may benefit from early switch to Faslodex/Ibrance

Less Radical, a podcast about Bernie Fisher, nominated for two Webby Awards

Less Radical, a documentary podcast that tells story of Bernie Fisher, a pioneering surgeon-scientist who redefined breast cancer treatment, was nominated for Best Podcast - Documentary and Best Indie Podcast – Limited Run in the 29th Annual Webby Awards.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Mass General study: Screenings for breast and colorectal cancer 4x higher than lung cancer

Although lung cancer screening is recommended in the U.S. for certain individuals with a history of smoking, only 18% of eligible individuals in the U.S. get screened.

April 04, 2025

Vol.51 No.13

Clinical Roundup

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

A study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer to develop resistance to therapy. Researchers at Baylor College of Medicine showed that lipid accumulation in tumor cells and nearby immune cells promotes immune suppression, but disrupting lipid formulation reverses treatment resistance and the immunosuppressive microenvironment.

April 04, 2025

Vol.51 No.13

In the Archives

Breast cancer activists in the 90s got DOD to fund cancer research—now that program has been gutted

In 1991, the National Breast Cancer Coalition demanded that the federal government spend $300 million more on breast cancer research. This push resulted in the creation of the Department of Defense Congressionally Directed Medical Research Program, which has broadened to 34 other diseases with an FY24 budget of $1.5 billion.

March 28, 2025

Vol.51 No.12

In Brief

Karen Knudsen joins Paradigm Health’s board of directors as company prepares launch of AI-driven clinical trial data collection and management application

Paradigm Health announced on March 20 the appointment of Karen E. Knudsen to its board of directors, alongside the upcoming launch of its eSource clinical trial data application.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Orca Bio, a late-stage biotechnology company, on March 17 announced results from the pivotal phase III Precision-T study of Orca-T, its lead investigational allogeneic T-cell immunotherapy, in patients with acute myeloid leukemia, acute lymphoblastic leukemia, high-risk myelodysplastic syndrome and mixed-phenotype acute leukemia. Orca-T is manufactured using highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors.

March 28, 2025

Vol.51 No.12

Breast cancer patients with ER mutations may benefit from early switch to Faslodex/Ibrance

YOU MAY BE INTERESTED IN

Less Radical, a podcast about Bernie Fisher, nominated for two Webby Awards

Mass General study: Screenings for breast and colorectal cancer 4x higher than lung cancer

Fatty acids promote immune suppression and therapy resistance in triple negative breast cancer, Baylor Medicine study finds

Breast cancer activists in the 90s got DOD to fund cancer research—now that program has been gutted

Karen Knudsen joins Paradigm Health’s board of directors as company prepares launch of AI-driven clinical trial data collection and management application

Investigational Orca-T treatment for hematologic malignancies meets primary endpoint in phase III trial

Renew today!

Subscriber content